List of Kloxxado drug patents
Kloxxado is owned by Hikma.
Kloxxado contains Naloxone Hydrochloride.
Kloxxado has a total of 3 drug patents out of which 0 drug patents have expired.
Kloxxado was authorised for market use on 29 April, 2021.
Kloxxado is available in spray;nasal dosage forms.
Kloxxado can be used as use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients.
The generics of Kloxxado are possible to be released after 26 August, 2034.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10973814 | HIKMA | Liquid naloxone spray |
Aug, 2034
(11 years from now) | |
| US10722510 | HIKMA | Liquid naloxone spray |
Aug, 2034
(11 years from now) | |
| US11135155 | HIKMA | Liquid naloxone spray |
Aug, 2034
(11 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 April, 2021
Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients
Dosage: SPRAY;NASAL
KLOXXADO family patents
13
United States
3
Japan
2
Canada
2
European Union
1
Morocco
1
Australia
1
China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic